{
    "organizations": [],
    "uuid": "ba4d3749ac0b6d29023e176ccf12d719a285785f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-abeona-receives-fda-orphan-drug-st/brief-abeona-receives-fda-orphan-drug-status-for-gene-therapy-to-treat-rare-disease-in-newborns-idUSASB0C57H",
    "ord_in_thread": 0,
    "title": "BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Abeona Therapeutics Inc:\n* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE\n* ABEONA THERAPEUTICS INC - ABO-202 IS ANTICIPATED TO ENTER CLINICAL TRIALS IN 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-12T21:51:00.000+02:00",
    "crawled": "2018-02-13T16:02:59.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "abeona",
        "therapeutic",
        "inc",
        "abeona",
        "therapeutic",
        "receives",
        "fda",
        "orphan",
        "drug",
        "designation",
        "gene",
        "therapy",
        "program",
        "infantile",
        "batten",
        "disease",
        "abeona",
        "therapeutic",
        "inc",
        "anticipated",
        "enter",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}